Table 1 Demographics and Clinical Characteristics
From: A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine
|  | Galcanezumab 120 mg N = 135 | Galcanezumab 240 mg N = 135 |
|---|---|---|
Age in years, mean (SD) | 40.2 (11.7) | 43.7 (11.0)* |
Female, n (%) | 110 (81.5) | 113 (83.7) |
Body mass index, kg/m2, mean (SD) | 26.6 (5.4) | 27.2 (5.8) |
Race, n (%) | ||
 Asian | 2 (1.5) | 0 |
 Black | 6 (4.4) | 8 (5.9) |
 Multiple | 23 (17.0) | 19 (14.1) |
 White | 103 (76.3) | 108 (80.0) |
Episodic migraine, n (%) | 109 (80.7) | 104 (77.0) |
Cardiovascular Disease Risk Group, n (%)a | 22 (17.1) | 28 (19.9) |
Comorbid conditions, mean (SD)b | 4.3 (3.2) | 4.7 (3.4) |
 Depression | 19 (14.1) | 26 (19.3) |
 Seasonal Allergy | 24 (17.8) | 21 (15.6) |
 Drug hypersensitivity | 21 (15.6) | 21 (15.6) |
 Back pain | 18 (13.3) | 21 (15.6) |
 Insomnia | 19 (14.1) | 20 (14.8) |
 Anxiety | 15 (11.1) | 16 (11.9) |
 Gastroesophageal reflux disease | 12 (8.9) | 16 (11.9) |
Years since diagnosis, mean (SD) | 20.2 (12.4) | 21.3 (12.5) |
Number of migraine headache days, mean (SD) | 9.7 (5.8) | 11.4 (6.7)* |
Number of headache days, mean (SD) | 5.0 (6.8) | 6.1 (8.1) |
Number of days with acute migraine medication use, mean (SD) | 9.8 (6.6) | 10.9 (7.2) |
Prior preventive treatment, n (%) | 81 (60.0) | 88 (65.2) |
Patient Global Impression - Severity, mean (SD) | 4.7 (1.2) | 4.7 (1.2) |
Migraine Disability Assessment total, mean (SD) | 45.8 (42.1) | 54.0 (61.2) |
Migraine-Specific Questionnaire Role Function-Restrictive domain score, mean (SD) | 47.4 (19.2) | 47.7 (18.4) |